leider auf englisch
Toyama Chemical(von Ulrich14 erwähnt) wird in Frankfurt gehandelt (oder auch nicht da kein Volumen)WKN 862908
ist aber ein hochinteressanter Biotechwert mit einem Antibakteriellen Wirkstoff für den Toyama gerade mit Schering Plough eine Lizenz vereinbart hat im Wert von 80 millionen $
biz.yahoo.com/prnews/040331/nyw043_1.html
Under the terms contemplated by the letter of intent, Toyama would receive a payment from Schering-Plough of $80 million upon definitive agreements being reached and becoming effective. Schering-Plough would expense this amount at that time, which the company expects to occur in the second quarter of 2004. Toyama could also receive additional milestone payments totaling up to $245 million based on the approval, further development and commercialization of garenoxacin. The substantial majority of such milestones will be based on the achievement of certain sales levels for garenoxacin. In addition, Toyama would also receive royalty payments on net sales of garenoxacin by Schering-Plough in its territories. The closing of the definitive agreements will be subject to the satisfaction of certain conditions.
Originally discovered by Toyama, garenoxacin is a novel quinolone antibacterial agent that has completed Phase III development. It has shown potent activity against a wide range of Gram-positive and Gram-negative bacterial pathogens, including anaerobic organisms, and resistant strains such as penicillin-resistant Streptococcus pneumoniae. Garenoxacin may offer a significant advance in its treatment category, with the potential to address bacterial strains resistant to other antibiotics with a favorable side effect profile. Toyama had previously licensed garenoxacin on a worldwide basis, excluding Japan, to Bristol-Myers Squibb. On October 16, 2003, Toyama reacquired all rights pertaining to garenoxacin from Bristol-Myers Squibb.
aber auch Advantest legt los,hier gibts auch einen OS von Citigroup WKN 729827
A news report that the company expected operating profit to double to 60 billion yen ($579 million) in the 2004/05 financial year, which started on Thursday, also helped draw buyers.
wie Reuters heute meldet legte der Chipverkauf um 31% weltweit zu
biz.yahoo.com/rb/040402/tech_chips_sales_1.html
Electronics component maker Rohm Co tacked on 3.51 percent to 13,580 yen on the Osaka Securities Exchange, while Kyocera Corp gained 2.85 percent to 9,010 yen.
NEC Corp added 3.42 percent to 877, helped after the company said it had developed a new battery which could be recharged in 30 seconds, compared with current nickel-hydrogen batteries, which take about one hour to recharge.
The stock also got a boost from chip maker Elpida Memory Inc, NEC's joint venture with Hitachi Ltd, which said on Thursday it would buy land and production facilities from an NEC subsidiary in Japan to boost its operational efficiency.
Auto stocks were unfazed by the yen's strength, especially after industry data on Thursday showed strong March sales in the United States.
Nissan, Japan's third-biggest car maker, was up 1.49 percent at 1,160 yen and Toyota Motor, the world's number two auto maker, climbed 1.07 percent to 3,780 yen.
Elsewhere, Kanebo Ltd soared 26.77 percent to 161 yen to become the top gainer among the Nikkei's 225 components.
Investors cheered a report in financial daily Nihon Keizai Shimbun on Friday that China's biggest drug maker, Sanjiu Enterprise Group, was interested in buying the drug business of Kanebo.
The cosmetics maker is undergoing rehabilitation with the help of a state-backed corporate restructuring body, which last month announced a 366 billion yen ($3.53 billion) bailout.
Nihon Keizei Shimbun ist die beste Finanzzeitung auf englisch,kostet für Auswärtige aber 48EUR bzw 6000 Yen im halben Jahr,Probeabo 14Tage möglich
Toyama Chemical(von Ulrich14 erwähnt) wird in Frankfurt gehandelt (oder auch nicht da kein Volumen)WKN 862908
ist aber ein hochinteressanter Biotechwert mit einem Antibakteriellen Wirkstoff für den Toyama gerade mit Schering Plough eine Lizenz vereinbart hat im Wert von 80 millionen $
biz.yahoo.com/prnews/040331/nyw043_1.html
Under the terms contemplated by the letter of intent, Toyama would receive a payment from Schering-Plough of $80 million upon definitive agreements being reached and becoming effective. Schering-Plough would expense this amount at that time, which the company expects to occur in the second quarter of 2004. Toyama could also receive additional milestone payments totaling up to $245 million based on the approval, further development and commercialization of garenoxacin. The substantial majority of such milestones will be based on the achievement of certain sales levels for garenoxacin. In addition, Toyama would also receive royalty payments on net sales of garenoxacin by Schering-Plough in its territories. The closing of the definitive agreements will be subject to the satisfaction of certain conditions.
Originally discovered by Toyama, garenoxacin is a novel quinolone antibacterial agent that has completed Phase III development. It has shown potent activity against a wide range of Gram-positive and Gram-negative bacterial pathogens, including anaerobic organisms, and resistant strains such as penicillin-resistant Streptococcus pneumoniae. Garenoxacin may offer a significant advance in its treatment category, with the potential to address bacterial strains resistant to other antibiotics with a favorable side effect profile. Toyama had previously licensed garenoxacin on a worldwide basis, excluding Japan, to Bristol-Myers Squibb. On October 16, 2003, Toyama reacquired all rights pertaining to garenoxacin from Bristol-Myers Squibb.
aber auch Advantest legt los,hier gibts auch einen OS von Citigroup WKN 729827
A news report that the company expected operating profit to double to 60 billion yen ($579 million) in the 2004/05 financial year, which started on Thursday, also helped draw buyers.
wie Reuters heute meldet legte der Chipverkauf um 31% weltweit zu
biz.yahoo.com/rb/040402/tech_chips_sales_1.html
Electronics component maker Rohm Co tacked on 3.51 percent to 13,580 yen on the Osaka Securities Exchange, while Kyocera Corp gained 2.85 percent to 9,010 yen.
NEC Corp added 3.42 percent to 877, helped after the company said it had developed a new battery which could be recharged in 30 seconds, compared with current nickel-hydrogen batteries, which take about one hour to recharge.
The stock also got a boost from chip maker Elpida Memory Inc, NEC's joint venture with Hitachi Ltd, which said on Thursday it would buy land and production facilities from an NEC subsidiary in Japan to boost its operational efficiency.
Auto stocks were unfazed by the yen's strength, especially after industry data on Thursday showed strong March sales in the United States.
Nissan, Japan's third-biggest car maker, was up 1.49 percent at 1,160 yen and Toyota Motor, the world's number two auto maker, climbed 1.07 percent to 3,780 yen.
Elsewhere, Kanebo Ltd soared 26.77 percent to 161 yen to become the top gainer among the Nikkei's 225 components.
Investors cheered a report in financial daily Nihon Keizai Shimbun on Friday that China's biggest drug maker, Sanjiu Enterprise Group, was interested in buying the drug business of Kanebo.
The cosmetics maker is undergoing rehabilitation with the help of a state-backed corporate restructuring body, which last month announced a 366 billion yen ($3.53 billion) bailout.
Nihon Keizei Shimbun ist die beste Finanzzeitung auf englisch,kostet für Auswärtige aber 48EUR bzw 6000 Yen im halben Jahr,Probeabo 14Tage möglich
&a=862908&b=0&banner_ref=HASH(0x9ae1ec0)&zeitraum=6&ind_volume=ON&zoom.x=0&zeitbis=&bis=1080923052.60193&bname=&cookies=HASH(0x974bbac)&req_host=ARRAY(0x9ad86dc)&zeitvon=0&von=0 "ariva.de")
